|Event Time:||Sunday April 22, 2018 1:00 pm to 3:00 pm|
|Description:||A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.|
|2:35 PM - 3:00 PM||Discussion||Faculty|
|1:00 PM||001||Characterization of Atxn2 in ALS Patient Samples and Insight into ASO Therapy||
Dr. Taylor has nothing to disclose.
|1:12 PM||002||Quantitative Determination of SMN2 Copy Number using Next Generation Sequencing and Correlation to Disease Severity||
Dr. Westbrook has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Invitae.
|1:24 PM||003||Effects of Elamipretide in Adults with Primary Mitochondrial Myopathy: a Phase 2 Double-Blind, Randomized, Placebo-Controlled Crossover Trial (MMPOWER-2)||
Bruce Cohen, MD, FAAN
Dr. Cohen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Stealth Biotheraputics. Dr. Cohen has received research support from Stealth Biotherapeutics, BioElectron Technologies, Reata Pharmaceuticals, Horizon Pharmaceuticals.
|1:36 PM||004||Modulation of Transcriptomic Changes in Alzheimer Disease by Ethnicity||
Sathesh K. Sivasankaran
Dr. Sivasankaran has nothing to disclose.
|1:48 PM||005||Canagliflozin Associated with MELAS Pseudoexacerbation||
Dr. Dewan has nothing to disclose.
|2:00 PM||006||Inotersen Improves Norfolk Quality of Life-Diabetic Neuropathy Measures in Patients With Hereditary Transthyretin Amyloidosis with Polyneuropathy in the Phase 3 Study NEURO-TTR||
Michael J. Polydefkis, MD, FAAN
Dr. Polydefkis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer and Alnylam.
|2:12 PM||007||Variation of Penetrance estimates in a wide spectrum of TTR-FAP families: implication for management of carriers||
Dr. Gorram has nothing to disclose.
|2:24 PM||008||Glycemic Control Boosts Glucosylated Nanocarrier Crossing the BBB into the Brain||
Hiroya Kuwahara, MD, PhD
Dr. Kuwahara has nothing to disclose.
Ready to register for the 2018 AAN Annual Meeting?
|7:00 AM-7:45 AM|
|Yoga (All-Levels Vinyasa)||Jamie Heath MD|
|7:00 AM-9:00 AM|
|C216||Neuroendocrine Update: Nuts and Bolts of What You Need to Know||Alison Pack MD|
|C220||Drugs and Toxin-induced Neurologic Emergencies||Sara Hocker MD|
|11:30 AM-5:30 PM|
|P6||Poster Session VI|
|12:00 PM-12:30 PM|
|How to Bridge to Careers in Industry||Jose Cavazos MD, PhD, FAAN|
|12:00 PM-12:45 PM|
|Outsmart Stress||Marie Pasinski MD|
|12:00 PM-1:00 PM|
|The Neurology of Creativity at the Keyboard||Phillip Pearl MD, FAAN|
|1:00 PM-3:00 PM|
|C228||Neuroimaging for the General Neurologist I: Brain||Jennifer McVige MD|
|C230||Neurologic Complications of Medical and Surgical Therapies||Sara Hocker MD|
|C233||Actualización Científica Durante el Congreso Anual II||Jose Cavazos MD, PhD, FAAN|
|S50||Updates in General Neurology|
|3:30 PM-5:30 PM|
|C237||Neurologic Complications of Medical Disease||Sara Hocker MD|
|C240||Neuroimaging for the General Neurologist II: Brain||Jennifer McVige MD|